PAVmed Inc (PAVM)
NASDAQ:PAVM
PAVM Stock Chart & Stats
$7.75
$0.11(1.44%)
At close: 4:00 PM EST
$7.75
$0.11(1.44%)
Day’s Range― - ―
52-Week Range$6.00 - $28.44
Previous Close$8
Volume99.04K
Average Volume (3M)377.79K
Market Cap
$13.38M
Enterprise Value$10.83M
Total Cash (Recent Filing)$3.10M
Total Debt (Recent Filing)$9.28M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.70
Shares Outstanding1,496,696
10 Day Avg. Volume774,204
30 Day Avg. Volume377,786
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.43
Price to Sales (P/S)2.03
P/FCF Ratio-0.18
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue373.56
Enterprise Value/Gross Profit-55.84
Enterprise Value/Ebitda6.73
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-24
Revenue Forecast (FY)$490.00K
Bulls Say, Bears Say
Bulls Say
Corporate Strategy And ValuationLaunch of the PMX incubator combined with an analyst move to a higher 12-month price target signals potential for new asset creation and perceived upside beyond core device sales.
Medicare ReimbursementImminent Medicare coverage expected in 2026 for procedures tied to Lucid's platform could expand reimbursement pathways for PAVmed technologies, supporting broader patient access and revenue growth.
Strategic Partnerships And Digital HealthStrategic partnership with The Ohio State's James Cancer Hospital to pilot Veris Health's personalized digital cancer-care tools and development of a biopharma companion module targeting FDA clearance may validate clinical utility and accelerate adoption alongside new oncology therapeutics.
Bears Say
Competitive RiskProlonged commercialization challenges could enable competitors to capture market share, limiting revenue upside even if PAVmed's products eventually reach the market.
Development And Regulatory RiskOngoing development and regulatory hurdles for PAVmed's devices create execution risk that could delay product approvals and market entry, weighing on near-term growth expectations.
Financing And Dilution RiskExtended development timelines may increase financing needs, raising the risk of equity dilution or costly capital raises that can pressure the stock.
PAVmed News
PAVM FAQ
What was PAVmed Inc’s price range in the past 12 months?
PAVmed Inc lowest stock price was $6.00 and its highest was $28.44 in the past 12 months.
What is PAVmed Inc’s market cap?
PAVmed Inc’s market cap is $13.38M.
When is PAVmed Inc’s upcoming earnings report date?
PAVmed Inc’s upcoming earnings report date is May 18, 2026 which is in 51 days.
How were PAVmed Inc’s earnings last quarter?
PAVmed Inc released its earnings results on Nov 13, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$5.4 by $5.11.
Is PAVmed Inc overvalued?
According to Wall Street analysts PAVmed Inc’s price is currently Overvalued.
Does PAVmed Inc pay dividends?
PAVmed Inc does not currently pay dividends.
What is PAVmed Inc’s EPS estimate?
PAVmed Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PAVmed Inc have?
PAVmed Inc has 1,496,696 shares outstanding.
What happened to PAVmed Inc’s price movement after its last earnings report?
PAVmed Inc reported an EPS of -$0.29 in its last earnings report, beating expectations of -$5.4. Following the earnings report the stock price went down -8.534%.
Which hedge fund is a major shareholder of PAVmed Inc?
Currently, no hedge funds are holding shares in PAVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PAVmed Inc
PAVmed Inc. is a medical technology company focused on the development and commercialization of innovative medical devices and diagnostic tools. Operating primarily in the healthcare sector, PAVmed aims to improve patient outcomes through its core products, which include devices for gastroenterology, urology, and other specialty areas. The company is known for its commitment to addressing unmet medical needs with solutions that enhance clinical workflows and patient care.
PAVM Company Deck
PAVM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several significant achievements, including successful Medicare endorsement for EsoGuard, strong financial positioning for Lucid, and strategic partnerships for Veris. However, challenges remain in debt restructuring and stagnant EsoGuard revenue growth.View all PAVM earnings summariesTechnical Analysis
Strata Skin Sciences
―
Biomerica
―
Co-Diagnostics
―
Tenon Medical, Inc.
―
Heart Test Laboratories, Inc.
―
Ownership Overview
Currently, No data available
---